Loading
Cellectar Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Jul 2025.
Cellectar Biosciences, Inc.: what insiders have been doing
Cellectar Biosciences, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 1 filing came from 1 insider.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €624. The largest single trade was a sale of €624 by Neis John, published on 16 December 2025.
A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,816 companies, median 19 filings), a count of 1 filing is below the norm. The full history, which starts in 2016, counts 6 purchases against 3 sales.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€152,946
6 ops. · all time
Sell Volume
€624
3 ops. · all time
Who traded when
BuySaleJarrod Longcor2 buys
Chad J. Kolean1 buy
James Caruso V1 buy
John Neis1 sale
Since the insiders bought
- -42.3%Entry US$4.80 · Close at T+365 US$2.77
- -42.3%Entry US$4.80 · Close at T+365 US$2.77
- -42.3%Entry US$4.80 · Close at T+365 US$2.77
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.57
Analyst consensus
4 analysts1.25/5
US$10.00Target US$11.50(+347%)US$15.00
Income statement
EBITDA-US$22.8M
Net income-US$21.8M0.0% margin
Valuation
PER (forward)-1.4x
P/Book3.9x
Beta0.56
Balance sheet & cash
Market capUS$20.5M
Total debtUS$409.6k
Free Cash Flow-US$23.1M
Debt / Equity32%
Profitability & ownership
ROE-290.4%
ROA-103.0%
% insiders2.1%
% institutions20.2%
Last declaration on 16 December 2025
Declarations14 total
5,000 shares@ US$4.99100.0% of flowCommon StockSEC:0001104659-25-065570:0
Canonical exit: 30 Sept 2025 (T+90)
10,000 shares@ US$4.99100.0% of flowCommon StockSEC:0001104659-25-065573:0
Canonical exit: 30 Sept 2025 (T+90)
10,000 shares@ US$4.9983.8% of flowCommon StockSEC:0001104659-25-065572:0
Canonical exit: 30 Sept 2025 (T+90)
30,000 shares@ US$0.2816.2% of flowCommon StockSEC:0001104659-25-023121:0
Canonical exit: 10 Apr 2025 (T+90)
47,856 shares0Common StockSEC:0001104659-23-125485:0
42,927 shares0Common StockSEC:0001104659-23-125484:0
39,599 shares0Common StockSEC:0001104659-23-125488:0
40,596 shares0Common StockSEC:0001104659-23-125483:0
42,554 shares0Common StockSEC:0001104659-23-125486:0
25,000 shares@ US$1.04100.0% of flowCommon StockSEC:0001104659-21-115477:0
Canonical exit: 13 Dec 2021 (T+90)
19,417 shares@ US$1.0426100.0% of flowCommon StockSEC:0001104659-21-113416:0
Canonical exit: 2 Dec 2021 (T+90)
64,747 sharesCommon StockSEC:0001535264-16-000116:0
35,253 sharesCommon StockSEC:0001535264-16-000116:1
14 of 14 declarations
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (ticker: CLRB) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. Its headquarters are in Florham Park, New Jersey. For investors, this is a classic small-cap clinical biotech story: valuation is driven primarily by pipeline execution, clinical readouts, regulatory milestones, and financing capacity rather than by a broad portfolio of marketed products.
The company’s identity is built around its proprietary Phospholipid Drug Conjugate (PDC) platform, which is designed to selectively deliver therapeutic payloads to cancer cells while reducing off-target exposure. That platform is central to its competitive thesis. Cellectar describes itself as a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of proprietary cancer therapies, both independently and through research and development collaborations.
Read moreShow less
Cellectar’s lead program is iopofosine I 131, a PDC designed to deliver iodine-131 in a targeted manner. The company states that this asset has received Breakthrough Therapy Designation from the FDA, which can enhance the program’s visibility and development momentum, although it does not guarantee approval. The pipeline also includes CLR 121225, an actinium-225-based program being developed for several solid tumors with significant unmet medical need, alongside preclinical PDC chemotherapeutic programs and partnered assets. In other words, the company remains highly pipeline-dependent, which is typical for a biotech at this stage.
From a competitive standpoint, Cellectar operates in a crowded oncology landscape that includes large pharmaceutical companies, specialty biotechs, and an expanding radiopharmaceutical ecosystem. Its potential advantage lies less in scale and more in scientific differentiation: a targeted delivery technology that aims to improve efficacy and safety in difficult-to-treat cancers. The business footprint is predominantly U.S.-centered, with clinical and corporate activities anchored in the United States and broader partnering opportunities depending on the program.
Recent corporate developments have also shaped the investment case. In June 2025, Cellectar announced a 1-for-30 reverse stock split, effective June 24, 2025, with the shares continuing to trade on the NASDAQ after the split. Such actions are often associated with maintaining exchange compliance and supporting share-price optics. The company was also notified in 2024 about a filing delay related to financial statement restatements, reflecting the operational and reporting risks that can accompany development-stage biotech names. More recently, SEC filings show new Form 4 insider transaction activity in May 2026, underscoring continued insider monitoring by market participants. Overall, CLRB should be viewed as a high-risk, event-driven oncology biotech with meaningful scientific optionality but substantial clinical and financing risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
